The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
M | Musculo-skeletal system | |
2
|
M04 | Antigout preparations | |
3
|
M04A | Antigout preparations | |
4
|
M04AA | Preparations inhibiting uric acid production |
| Code | Title | |
|---|---|---|
| M04AA01 | Allopurinol | |
| M04AA02 | Tisopurine | |
| M04AA03 | Febuxostat | |
| M04AA51 | Allopurinol, combinations |
| Active Ingredient |
|---|
|
Allopurinol is a xanthine-oxidase inhibitor. Allopurinol and its main metabolite oxipurinol lower the level of uric acid in plasma and urine by inhibition of xanthine oxidase, the enzyme catalyzing the oxidation of hypoxanthine to xanthine and xanthine to uric acid. |
|
Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO. |
|
|
| Document | Type | Information Source | |
|---|---|---|---|
| ADENURIC Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| ULORIC Tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| ZYLOPRIM Tablet | MPI, US: SPL/Old | FDA, National Drug Code (US) | |
| ZYLORIC Tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |